APA (7th ed.) Citation

D, T., C, L., J, G., Q, C., X, L., Y, W., . . . S, Y. (2026). Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production. Clinical and molecular hepatology, 32(1), 221. https://doi.org/10.3350/cmh.2025.0577

Chicago Style (17th ed.) Citation

D, Tu, et al. "Gut Microbiota-mediated Berberine Metabolism Ameliorates Cholestatic Liver Disease by Suppressing 5-hydroxytryptamine Production." Clinical and Molecular Hepatology 32, no. 1 (2026): 221. https://doi.org/10.3350/cmh.2025.0577.

MLA (9th ed.) Citation

D, Tu, et al. "Gut Microbiota-mediated Berberine Metabolism Ameliorates Cholestatic Liver Disease by Suppressing 5-hydroxytryptamine Production." Clinical and Molecular Hepatology, vol. 32, no. 1, 2026, p. 221, https://doi.org/10.3350/cmh.2025.0577.